shutterstock_1123492958_willy_barton
Willy Barton / Shutterstock.com
28 August 2019Big PharmaSaman Javed

Ionis licenses chronic hepatitis B treatments to GSK

Biotech company Ionis Pharmaceuticals is to license its antisense medicines, used to treat people with chronic hepatitis B, to GlaxoSmithKline ( GSK).

In an announcement yesterday, August 27, Ionis said GSK had decided to agree on licensing the programme following positive phase two results.

Chronic hepatitis B is a viral infection of the liver that can lead to significant and potentially fatal health conditions such as liver failure and liver cancer.

As part of the agreement, Ionis is eligible to receive milestone payments of up to $262 million, including a $25 million licence fee, as well as tiered royalties “in the low double digits” on net sales.

According to the press release, GSK is now responsible or all development, regulatory and commercialisation activities and costs. 

Brett Monia, chief operating officer at Ionis, said the antisense technology “can potentially deliver a transformative medicine” for sufferers.

He added: "We believe GSK's expertise in infectious diseases makes them the ideal partner to help address this high unmet need."

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
25 July 2019   Growth in GlaxoSmithKline’s vaccines and consumer healthcare divisions has managed to partly counter the impact of generic versions of Advair on its sales.
Americas
10 July 2019   US authorities are seeking the extradition of a Chinese researcher from Switzerland for his part in a conspiracy to steal trade secrets from British pharmaceutical company GlaxoSmithKline.

More on this story

Big Pharma
25 July 2019   Growth in GlaxoSmithKline’s vaccines and consumer healthcare divisions has managed to partly counter the impact of generic versions of Advair on its sales.
Americas
10 July 2019   US authorities are seeking the extradition of a Chinese researcher from Switzerland for his part in a conspiracy to steal trade secrets from British pharmaceutical company GlaxoSmithKline.

More on this story

Big Pharma
25 July 2019   Growth in GlaxoSmithKline’s vaccines and consumer healthcare divisions has managed to partly counter the impact of generic versions of Advair on its sales.
Americas
10 July 2019   US authorities are seeking the extradition of a Chinese researcher from Switzerland for his part in a conspiracy to steal trade secrets from British pharmaceutical company GlaxoSmithKline.